[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004028440A3 - Vr1 antagonists for the treatment of urological disorders - Google Patents

Vr1 antagonists for the treatment of urological disorders Download PDF

Info

Publication number
WO2004028440A3
WO2004028440A3 PCT/EP2003/010111 EP0310111W WO2004028440A3 WO 2004028440 A3 WO2004028440 A3 WO 2004028440A3 EP 0310111 W EP0310111 W EP 0310111W WO 2004028440 A3 WO2004028440 A3 WO 2004028440A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
treatment
urological disorders
prophylaxis
antagonist
Prior art date
Application number
PCT/EP2003/010111
Other languages
French (fr)
Other versions
WO2004028440A2 (en
Inventor
Masahiro Shiroo
Takeshi Yura
Noriyuki Yamamoto
Masomi Tajimi
Yasuhiro Tsukimi
Original Assignee
Bayer Healthcare Ag
Masahiro Shiroo
Takeshi Yura
Noriyuki Yamamoto
Masomi Tajimi
Yasuhiro Tsukimi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Masahiro Shiroo, Takeshi Yura, Noriyuki Yamamoto, Masomi Tajimi, Yasuhiro Tsukimi filed Critical Bayer Healthcare Ag
Priority to AU2003273856A priority Critical patent/AU2003273856A1/en
Publication of WO2004028440A2 publication Critical patent/WO2004028440A2/en
Publication of WO2004028440A3 publication Critical patent/WO2004028440A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods for treating urological disorders. More particularly, this invention concerns the use of a vanilloid receptor (VR1) antagonist for the prophylaxis and treatment of urinary incontinence and overactive bladder. Such antagonists can be N-phenyl-N’-naphthyl urea derivatives or antibodies immunoreactive with VR1.
PCT/EP2003/010111 2002-09-24 2003-09-11 Vr1 antagonists for the treatment of urological disorders WO2004028440A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003273856A AU2003273856A1 (en) 2002-09-24 2003-09-11 Vr1 antagonists for the treatment of urological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021367.4 2002-09-24
EP02021367 2002-09-24

Publications (2)

Publication Number Publication Date
WO2004028440A2 WO2004028440A2 (en) 2004-04-08
WO2004028440A3 true WO2004028440A3 (en) 2004-07-15

Family

ID=32039089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010111 WO2004028440A2 (en) 2002-09-24 2003-09-11 Vr1 antagonists for the treatment of urological disorders

Country Status (2)

Country Link
AU (1) AU2003273856A1 (en)
WO (1) WO2004028440A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055004A1 (en) 2002-12-13 2004-07-01 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
US7566712B2 (en) 2003-07-16 2009-07-28 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
WO2005035471A1 (en) 2003-10-14 2005-04-21 Ajinomoto Co., Inc. Ether derivative
WO2008024438A2 (en) 2006-08-23 2008-02-28 Neurogen Corporation 2-phenoxy pyrimidinone analogues
US8128591B2 (en) 2008-11-10 2012-03-06 Warsaw Orthopedic, Inc. Multiple component mixing and delivery system
DE102022104759A1 (en) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-crystal screening method, in particular for the production of co-crystals

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009970A1 (en) * 1997-08-28 1999-03-04 Afferon Corporation Urinary incontinence therapy
WO2000032766A1 (en) * 1998-12-01 2000-06-08 Glaxo Group Limited Human vanilloid receptors and their uses
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
WO2002016318A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002072536A1 (en) * 2001-03-09 2002-09-19 Smithkline Beecham P.L.C. Urea derivatives having vanilloid receptor (vr1) antagonist activity
WO2003014064A1 (en) * 2001-07-31 2003-02-20 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
WO2003055484A1 (en) * 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives
WO2003095420A1 (en) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Hydroxy tetrahydro-naphthalenylurea derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009970A1 (en) * 1997-08-28 1999-03-04 Afferon Corporation Urinary incontinence therapy
WO2000032766A1 (en) * 1998-12-01 2000-06-08 Glaxo Group Limited Human vanilloid receptors and their uses
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
WO2002016318A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002072536A1 (en) * 2001-03-09 2002-09-19 Smithkline Beecham P.L.C. Urea derivatives having vanilloid receptor (vr1) antagonist activity
WO2003014064A1 (en) * 2001-07-31 2003-02-20 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
WO2003055484A1 (en) * 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives
WO2003095420A1 (en) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Hydroxy tetrahydro-naphthalenylurea derivatives

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDERSSON K E ET AL: "The pharmacological treatment of urinary incontinence.", BJU INTERNATIONAL. DEC 1999, vol. 84, no. 9, December 1999 (1999-12-01), pages 923 - 947, XP002282292, ISSN: 1464-4096 *
BIRDER L A ET AL: "VANILLOID RECEPTOR EXPRESSION SUGGESTS A SENSORY ROLE FOR URINARY BLADDER EPITHELIAL CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 23, 6 November 2001 (2001-11-06), pages 13396 - 13401, XP001191204, ISSN: 0027-8424 *
GROAT DE W C ET AL: "ABNORMAL DESENSITIZATION OF VR1 AND HYPEREXCITABILITY OF DRG NEURONS FROM CATS WITH INTERSTITIAL CYSTITIS", ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 27, no. 2, 2001, pages 2163, XP001191206, ISSN: 0190-5295 *
MAGGI C A ET AL: "A COMPARISON OF CAPSAZEPINE AND RUTHENIUM RED AS CAPSAICIN ANTAGONISTS IN THE RAT ISOLATED URINARY BLADDER AND VAS DEFERENS", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 108, no. 3, March 1993 (1993-03-01), pages 801 - 805, XP008030582, ISSN: 0007-1188 *
NOSAKA K ET AL: "AMELIORATION BY CAPSAZEPINE, A VANILLOID RECEPTOR ANTAGONIST, OF LOW PH-INDUCED POLLAKIURIA IN ANESTHETIZED GUINEA-PIGS", JAPANESE JOURNAL OF PHARMACOLOGY, THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JP, vol. 73, no. SUPPL 1, 22 March 1997 (1997-03-22), pages 268P, XP008030620, ISSN: 0021-5198 *
SZALLASI A ET AL: "COMPETITIVE INHIBITION BY CAPSAZEPINE OF U2HRESINIFERATOXIN BINDING TO CENTRAL (SPINAL CORD AND DORSAL ROOT GANGLIA) AND PERIPHERAL (URINARY BLADDER AND AIRWAYS) VANILLOID (CAPSAICIN) RECEPTORS IN THE RAT", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 267, no. 2, 1 November 1993 (1993-11-01), pages 728 - 733, XP002059192, ISSN: 0022-3565 *
YIANGOU Y ET AL: "Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder.", BJU INTERNATIONAL. JUN 2001, vol. 87, no. 9, June 2001 (2001-06-01), pages 774 - 779, XP002282291, ISSN: 1464-4096 *

Also Published As

Publication number Publication date
AU2003273856A8 (en) 2004-04-19
WO2004028440A2 (en) 2004-04-08
AU2003273856A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
WO2002066427A3 (en) (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
CA2534542A1 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
WO2004021989A3 (en) Imidazolopyridines and methods of making and using the same
WO2006062981A3 (en) Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
WO2005082343A3 (en) Amines and amides for the treatment of diseases
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
WO2005072308A3 (en) Cgrp receptor antagonists
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
WO2006105117A3 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
MY144307A (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
WO1998036061A3 (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
WO2007011702A3 (en) Use of egfr inhibitors to prevent or treat obesity
WO2006104870A3 (en) Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
WO2002094767A3 (en) Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
WO2005040121A3 (en) Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
WO2004028440A3 (en) Vr1 antagonists for the treatment of urological disorders
MX2007007100A (en) Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof.
WO2005112903A3 (en) Use of ghrelin antagonists for improving cognition and memory
WO2004096196A3 (en) Treatment of incontinence with 5htc2 agonists
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
WO2005117979A3 (en) Use of il-17 in the treatment of fertility-related disorders
WO2002102978A3 (en) Human growth hormone antagonists
AU2003288200A8 (en) Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP